Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)
Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…Interval from onset of Parkinson disease to onset of motor and non-motor complications in Leucine-rich repeat kinase 2 (LRRK2) G2019S positive versus matched PD controls
Objective: To compare the latency between onset of Parkinson disease (PD) symptoms and onset of motor and non-motor complications of PD, between G2019S LRRK2 mutation…Spiral Analysis is a Promising Biomarker in LRRK2 G2019S carriers
Objective: To assess whether harboring a LRRK2 G2019S mutation is associated with abnormalities in spiral drawing, including in mutation carriers with Parkinson Disease (PD) as…Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients
Objective: We aim to estimate the frequency of mutations in the glucocerebrosidase gene (GBA) and LRRK2 G2019S in a yet unstudied Egyptian Parkinson's disease population from the…Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease
Objective: Our study aimed to evaluate neuromelanin-Magnetic Resonance signal changes in PD patients carrying a LRRK2 mutation. Background: Specific magnetic resonance (MR) sequences are able to…Data driven analysis for exploring phenotypic differences in patients with Parkinson’s disease with or without genetic mutations.
Objective: To explore, using a data driven statistical analysis method, discriminating phenotype features of disease in a large group of patients with Parkinson’s disease (PD)…Gene associated differences in pre-diagnostic symptoms of Parkinson’s Disease: a retrospective study
Objective: To investigate whether glucocerebrosidase (GBA) L444P and leucine-rich repeat kinase 2 (LRRK2) G2385R and R1628P mutations are associated with different symptoms and manifesting patterns…Motor and Nonmotor clinical phenotype in LRRK2 Parkinson’s disease patients: a Case-control study
Objective: Our study aimed to characterize and compare the clinical phenotype of LRRK2-PD patients with PD patients with no identified mutations. Background: The clinical phenotype…Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation
Objective: This study aimed to compare the alterations in the cortico-striatal functional connectivity (FC) of drug-naïve Parkinson’s disease (PD) patients with the leucine-rich repeat kinase…The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study
Objective: To evaluate the effects of leucine-rich repeat kinase 2 (LRRK2) mutations on the central cholinergic system in both manifesting and non-manifesting carriers using PET…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.